Psychedelics are being investigated in experimental protocols for certain psychiatric disorders. Psilocybin, LSD and MDMA are not approved as treatments for depression by major regulatory authorities; expedited designations or advanced studies are not equivalent to authorization.
Current studies do not propose a strictly “pharmacological” use, but rather the integration of psychedelic administration within a structured therapeutic pathway that includes preparation, assisted administration, and post-experience integration. This approach is known as psychedelic-assisted psychotherapy.
Changes in connectivity, the default mode network and entropy measures are hypotheses and research findings. Their causal relationship with psychological flexibility or antidepressant response has not been established.
Administration may produce intense subjective experiences, including altered consciousness, vivid imagery and insights. The causal relationship between these experiences, psychological support and antidepressant outcome has not been established.
Some controlled studies report rapid symptom reductions after one or a few administrations, but duration of effect, generalizability, maintenance of blinding and long-term safety remain uncertain.
Ayahuasca typically contains DMT and monoamine oxidase inhibitors and has pharmacology, duration, interactions and risks that differ from psilocybin; it is not correct to describe it simply as a similar, more intense and shorter experience.
In the main clinical protocols studied for depression, psychedelics are generally administered with psychological support or psychotherapy, within a structured therapeutic setting that includes:
Because there is no approved indication for depression, there is no antidepressant prescribing information with standard contraindications. Trials frequently exclude people with psychosis, bipolar disorder, cardiovascular instability or other risks; this should be described as a research criterion and precaution, not as a universal regulatory label.
Regulatory designations that expedite development, including FDA Breakthrough Therapy designation, are not equivalent to approval. As of 2026, psychedelics remain experimental treatments for depression and must be used only in authorized studies or programs.
Psilocybin and other psychedelics are under clinical investigation, generally with preparation and psychological support. The proposed mechanisms and the specific contribution of psychotherapeutic support remain under study; terms such as “deep restructuring” do not represent a standardized clinical outcome.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.